ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Pfizer and Changchun GeneScience Pharmaceutical side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

PfizerChangchun GeneScience Pharmaceutical
studies on the registry4,072112
open to participants now14647
phase 3 studies under way9911
reach primary completion within a year9118
programswith a study of their own in two years91+9 named only30

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phasePfizerChangchun GeneScience Pharmaceutical
Phase 1

Pfizer: 42 of its 91 programs at phase 1

  1. polfurmetinibphase 1
  2. claturafenibphase 1
  3. PF-07985631phase 1
  4. PF-08642534phase 1
  5. Anti-integrin Beta-6 Antibody-drug Conjugate PF-08046876phase 1

and 37 more — sign in to see them all

46%

Changchun GeneScience Pharmaceutical: 18 of its 30 programs at phase 1

  1. GENSCI098phase 1
  2. GENSCI142phase 1
  3. PEG-rhGH with new preparation (T)phase 1
  4. PEG-rhGH with present preparation (T)phase 1
  5. GENSCI128phase 1

and 13 more — sign in to see them all

60%
Phase 2

Pfizer: 10 of its 91 programs at phase 2

  1. PF-07328948phase 2
  2. tegtociclibphase 2
  3. PF-08653945phase 2
  4. PF-08049820phase 2
  5. ompekimigphase 2

and 5 more — sign in to see them all

11%

Changchun GeneScience Pharmaceutical: 7 of its 30 programs at phase 2

  1. GENSCI048phase 2
  2. GENSCI134phase 2
  3. GS1-144phase 2
  4. GENSCI120phase 2
  5. GENSCI136phase 2

and 2 more — sign in to see them all

23%
Phase 3

Pfizer: 31 of its 91 programs at phase 3

  1. berobenatidephase 3
  2. tivunatamigphase 3
  3. tilrekimigphase 3
  4. ritlecitinibphase 3
  5. abrysvophase 3

and 26 more — sign in to see them all

34%

Changchun GeneScience Pharmaceutical: 3 of its 30 programs at phase 3

  1. Cabergolinephase 3
  2. PEG-hGH Injectionphase 3
  3. leuprolide mesylatephase 3
10%
Approved, new studies

Pfizer: 8 of its 91 programs at approved, new studies

  1. rimegepantapproved, new study
  2. tucatinibapproved, new study
  3. elranatamabapproved, new study
  4. tisotumab vedotinapproved, new study
  5. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccineapproved, new study

and 3 more — sign in to see them all

9%

Changchun GeneScience Pharmaceutical: 2 of its 30 programs at approved, new studies

  1. Megestrol Acetateapproved, new study
  2. Human Growth Hormoneapproved, new study
7%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Pfizer37 readouts · 10 phase 3

Pfizer, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. rimegepantapproved, new study · Nov 29 · NCT06641466

Pfizer, Dec ’26: 8 programs whose next study reaches primary completion, 2 in phase 3

  1. ritlecitinibphase 3 · Dec 2 · NCT07029711
  2. vepdegestrantphase 3 · Dec 4 · NCT07231991
  3. VLA15phase 3 · Dec 4 · NCT07500506
  4. prifetrastatphase 3 · Dec 8 · NCT07721402
  5. disitamab vedotinphase 3 · Dec 11 · NCT04879329

and 3 more — sign in to see them all

Pfizer, Jan ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08653945phase 2 · Jan 13 · NCT07725809
  2. abrysvophase 3 · Jan 18 · NCT05035212
  3. berobenatidephase 3 · Jan 27 · NCT07508241

Pfizer, Feb ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. osivelotorphase 3 · Feb 8 · NCT06507904
  2. tilrekimigphase 3 · Feb 20 · NCT07792941
  3. PF-07328948phase 2 · Feb 23 · NCT07269301
  4. atirmociclibphase 3 · Feb 26 · NCT05262400
  5. mevrometostatphase 3 · Feb 28 · NCT06551324

Pfizer, Mar ’27: 3 programs whose next study reaches primary completion

  1. PG4phase 3 · Mar 4 · NCT06524414
  2. PF-08161842phase 1 · Mar 17 · NCT07897708
  3. PF-08103402phase 1 · Mar 30 · NCT07660731

Pfizer, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08642534phase 1 · Apr 21 · NCT07731139
  2. PG4 Multivalent Vaccinephase 3 · Apr 26 · NCT07794748

Pfizer, May ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. abrocitinibphase 3 · May 2 · NCT06807268
  2. marstacimabphase 3 · May 5 · NCT06703606

Pfizer, Jun ’27: 3 programs whose next study reaches primary completion

  1. PF-07832837phase 1 · Jun 2 · NCT06564389
  2. Pneumococcal 20-Valent Conjugate Vaccinephase 3 · Jun 10 · NCT07023081
  3. sigvotatug vedotinphase 3 · Jun 16 · NCT04389632
·

Pfizer, Aug ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. elranatamabapproved, new study · Aug 4 · NCT05317416
  2. zavegepantphase 3 · Aug 12 · NCT06995729
  3. claturafenibphase 1 · Aug 31 · NCT05355701
  4. polfurmetinibphase 1 · Aug 31 · NCT05538130

Pfizer, Sep ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. PF-08065010phase 1 · Sep 1 · NCT07235163
  2. ibuzatrelvirphase 3 · Sep 28 · NCT07013474
  3. remdesivirphase 3 · Sep 28 · NCT07013474

Pfizer, Oct ’27: 3 programs whose next study reaches primary completion

  1. tivunatamigphase 3 · Oct 18 · NCT07227012
  2. PA-001phase 1 · Oct 21 · NCT07086677
  3. PG4 in Buffer 1 with low dose PA-002phase 1 · Oct 21 · NCT07086677
Changchun GeneScience Pharmaceutical13 readouts · 3 phase 3

Changchun GeneScience Pharmaceutical, Nov ’26: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. Cabergolinephase 3 · Nov 21 · NCT07124221
  2. GENSCI134phase 2 · Nov 25 · NCT07016802

Changchun GeneScience Pharmaceutical, Dec ’26: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. polyethylene glycol-recombinant human growth hormonephase 2 · Dec 23 · NCT07260500
  2. Megestrol Acetateapproved, new study · Dec 31 · NCT07243379

Changchun GeneScience Pharmaceutical, Jan ’27: 2 programs whose next study reaches primary completion

  1. GENSCI142phase 1 · Jan 5 · NCT07663838
  2. GS1-144phase 2 · Jan 31 · NCT07491289

Changchun GeneScience Pharmaceutical, Feb ’27: 1 program whose next study reaches primary completion

  1. GENSCI136phase 2 · Feb 7 · NCT07366866
·

Changchun GeneScience Pharmaceutical, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. GENSCI155phase 1 · Apr 16 · NCT07638800
  2. Human Growth Hormoneapproved, new study · Apr 28 · NCT07691125

Changchun GeneScience Pharmaceutical, May ’27: 1 program whose next study reaches primary completion

  1. GENSCI161phase 1 · May 6 · NCT07476586
···

Changchun GeneScience Pharmaceutical, Sep ’27: 2 programs whose next study reaches primary completion

  1. GENSCI120phase 2 · Sep 0 · NCT07423533
  2. GENSCI098phase 1 · Sep 2 · NCT06569758

Changchun GeneScience Pharmaceutical, Oct ’27: 1 program whose next study reaches primary completion

  1. GENSCI164phase 1 · Oct 25 · NCT07790783
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Pfizer

New programs 6

Reached a new phase 0

None

Study stopped 3

  • PF-07868489phase 2 · terminated Nov 2 · none of its studies left running“The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.” · NCT07073820
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. T…” · NCT05573555
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. Th…” · NCT06125522

Primary completion later 6

Changchun GeneScience Pharmaceutical

New programs 2

Reached a new phase 1

  • GENSCI136phase 2 · Oct 27 · Autoimmune Diseases

Study stopped 1

  • GENSCI122phase 1 · terminated Nov 17 · none of its studies left running“The sponsor adjusted its research and development strategy” · NCT06772415

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 11 in all. A program counts in each condition its studies name most.

ConditionPfizerChangchun GeneScience Pharmaceutical
Carcinoma, Non-Small-Cell Lungboth · compare here

Pfizer in Carcinoma, Non-Small-Cell Lung: 9 programs

  1. tivunatamigphase 3
  2. prifetrastatphase 3
  3. disitamab vedotinphase 3
  4. sigvotatug vedotinphase 3
  5. ponsegromabphase 3

and 4 more — sign in to see them all

Their studies: Pfizer’s studies of Carcinoma, Non-Small-Cell Lung in search

Changchun GeneScience Pharmaceutical in Carcinoma, Non-Small-Cell Lung: 1 program

  1. Megestrol Acetateapproved, new study

Their studies: Changchun GeneScience Pharmaceutical’s studies of Carcinoma, Non-Small-Cell Lung in search

Dwarfism, Pituitaryboth · compare here

Pfizer in Dwarfism, Pituitary: 1 program

  1. Human Growth Hormoneapproved, new study

Their studies: Pfizer’s studies of Dwarfism, Pituitary in search

Changchun GeneScience Pharmaceutical in Dwarfism, Pituitary: 3 programs

  1. GENSCI134phase 2
  2. GS3-007a dry suspensionphase 2
  3. Human Growth Hormoneapproved, new study

Their studies: Changchun GeneScience Pharmaceutical’s studies of Dwarfism, Pituitary in search

Arthritis, Rheumatoidboth · compare here

Pfizer in Arthritis, Rheumatoid: 1 program

  1. ritlecitinibphase 3

Their studies: Pfizer’s studies of Arthritis, Rheumatoid in search

Changchun GeneScience Pharmaceutical in Arthritis, Rheumatoid: 2 programs

  1. GENSCI048phase 2
  2. GENSCI120phase 2

Their studies: Changchun GeneScience Pharmaceutical’s studies of Arthritis, Rheumatoid in search

Turner Syndromeboth · compare here

Pfizer in Turner Syndrome: 1 program

  1. Human Growth Hormoneapproved, new study

Their studies: Pfizer’s studies of Turner Syndrome in search

Changchun GeneScience Pharmaceutical in Turner Syndrome: 2 programs

  1. polyethylene glycol-recombinant human growth hormonephase 2
  2. Human Growth Hormoneapproved, new study

Their studies: Changchun GeneScience Pharmaceutical’s studies of Turner Syndrome in search

Cachexiaboth · compare here

Pfizer in Cachexia: 1 program

  1. ponsegromabphase 3

Their studies: Pfizer’s studies of Cachexia in search

Changchun GeneScience Pharmaceutical in Cachexia: 1 program

  1. Megestrol Acetateapproved, new study

Their studies: Changchun GeneScience Pharmaceutical’s studies of Cachexia in search

Dwarfismboth · compare here

Pfizer in Dwarfism: 1 program

  1. Human Growth Hormoneapproved, new study

Their studies: Pfizer’s studies of Dwarfism in search

Changchun GeneScience Pharmaceutical in Dwarfism: 1 program

  1. Human Growth Hormoneapproved, new study

Their studies: Changchun GeneScience Pharmaceutical’s studies of Dwarfism in search

Genetic Diseases, Inbornboth · compare here

Pfizer in Genetic Diseases, Inborn: 1 program

  1. Human Growth Hormoneapproved, new study

Their studies: Pfizer’s studies of Genetic Diseases, Inborn in search

Changchun GeneScience Pharmaceutical in Genetic Diseases, Inborn: 1 program

  1. Human Growth Hormoneapproved, new study

Their studies: Changchun GeneScience Pharmaceutical’s studies of Genetic Diseases, Inborn in search

Growth Disordersboth · compare here

Pfizer in Growth Disorders: 1 program

  1. Human Growth Hormoneapproved, new study

Their studies: Pfizer’s studies of Growth Disorders in search

Changchun GeneScience Pharmaceutical in Growth Disorders: 1 program

  1. Human Growth Hormoneapproved, new study

Their studies: Changchun GeneScience Pharmaceutical’s studies of Growth Disorders in search

Neoplasm Metastasisboth · compare here

Pfizer in Neoplasm Metastasis: 1 program

  1. tisotumab vedotinapproved, new study

Their studies: Pfizer’s studies of Neoplasm Metastasis in search

Changchun GeneScience Pharmaceutical in Neoplasm Metastasis: 1 program

  1. Megestrol Acetateapproved, new study

Their studies: Changchun GeneScience Pharmaceutical’s studies of Neoplasm Metastasis in search

Neoplasmsboth · compare here

Pfizer in Neoplasms: 1 program

  1. tucatinibapproved, new study

Their studies: Pfizer’s studies of Neoplasms in search

Changchun GeneScience Pharmaceutical in Neoplasms: 1 program

  1. Megestrol Acetateapproved, new study

Their studies: Changchun GeneScience Pharmaceutical’s studies of Neoplasms in search

Prostatic Neoplasmsboth · compare here

Pfizer in Prostatic Neoplasms: 1 program

  1. mevrometostatphase 3

Their studies: Pfizer’s studies of Prostatic Neoplasms in search

Changchun GeneScience Pharmaceutical in Prostatic Neoplasms: 1 program

  1. leuprolide mesylatephase 3

Their studies: Changchun GeneScience Pharmaceutical’s studies of Prostatic Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetPfizerChangchun GeneScience Pharmaceutical
ERBB2disitamab vedotin, tucatinibruleGENSCI139rule
GHRHuman Growth HormoneruleHuman Growth Hormonerule
A target, or a pathogen for a vaccine, known for: Pfizer 67 of 91 · Changchun GeneScience Pharmaceutical 7 of 30 programs (24 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Pfizer: 9).